A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors
Diseases and Conditions Researched
What is the purpose of this trial?
In Part 1, the primary objectives are to determine the safety and tolerability of BMS-982470 when administered weekly and 3 times weekly in combination with BMS-936558 to subjects with advanced or metastatic solid tumors and to identify a maximum tolerated dose (MTD).
In Part 2, the primary objective is to further characterize the safety and tolerability of BMS-982470 administered weekly and 3 times weekly in combination with BMS-936558 in subjects with clear cell renal cell carcinoma (ccRCC) or non-small cell lung cancer (NSCLC).
Click here for detailed participation information for this trial.
|Sponsor:||Bristol-Myers Squibb Company|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.